Cargando…
Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Recombinant adeno-associated virus (rAAV) has attracted a significant research focus for delivering genetic therapies to target cells. This non-enveloped virus has been trialed in many clinical-stage therapeutic strategies but important obstacle in clinical translation is the activation of both inna...
Autores principales: | Chu, Wing Sum, Ng, Joanne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049138/ https://www.ncbi.nlm.nih.gov/pubmed/33868303 http://dx.doi.org/10.3389/fimmu.2021.658038 |
Ejemplares similares
-
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
por: Shen, Weiran, et al.
Publicado: (2022) -
Corrigendum: rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
por: Shen, Weiran, et al.
Publicado: (2023) -
Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9
por: Okada, Hironori, et al.
Publicado: (2013) -
Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?
por: Zhan, Wei, et al.
Publicado: (2021) -
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
por: Esmagambetov, Ilias B., et al.
Publicado: (2023)